« Return to News | Clinical Intelligence

Quest, Genomic collaborate

Friday, July 15, 2011 10:25 AM

Quest Diagnostics and Genomic Vision announced a multi-year exclusive collaboration involving Genomic Vision's proprietary molecular combing genomic-analysis technology.

Quest Diagnostics has exclusive rights to develop and offer clinical- and research-use laboratory testing services based on Genomic Vision's molecular combing (also known as DNA combing) technique in the U.S., India and Mexico. Genomic Vision will retain rights to market new testing services that emerge from the collaboration's research and development in Europe (with the exception of the United Kingdom), the Middle East and Africa. Quest Diagnostics has also made an equity investment for an undisclosed sum in Genomic Vision.

DNA combing is an analytical technique that involves stretching coils of DNA into straight chains to facilitate direct high-resolution analysis of targeted areas of the human genome. The technique detects genetic mutations, most notably large scale gene rearrangements, which current DNA analytical technologies cannot detect.

Quest Diagnostics expects to validate and release the first laboratory developed test based on molecular combing, for aiding the detection of individuals affected with facioscapulohumeral muscular dystrophy, in 2012.

The companies will also focus on developing tests for cancer and neurological disorders, with testing services to be offered to clients of Quest Diagnostics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.